Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235296 | 0.82 | TSHR (0.35) | ALDH1A1LMNAKMT2ASLC22A12PSMB8 | |
| SCHEMBL1605524 | 0.82 | KCNN4 (0.41) | ALDH1A1LMNAKCNN4KMT2AHSP90AA1 | |
| SCHEMBL18189333 | 0.79 | SLC22A12 (0.31) | SLC22A12PSMB8 | |
| SCHEMBL11966007 | 0.77 | ALDH1A1 (0.48) | ALDH1A1LMNAPOLBKCNN4KMT2A | |
| SCHEMBL28679019 | 0.77 | CHRM3 (0.35) | ARGABRA1GABRB2 | |
| SCHEMBL16897504 | 0.77 | ALDH1A1 (0.32) | ALDH1A1GABRA1GABRB2 | |
| SCHEMBL22542073 | 0.77 | DYRK1A (0.30) | ALDH1A1KMT2ASLC22A12MAPTKDM4E | |
| SCHEMBL22542044 | 0.77 | CYP1A2 (0.31) | ALDH1A1LMNASLC22A12 | |
| SCHEMBL779328 | 0.75 | PSMB8 (0.35) | ALDH1A1LMNAKMT2APSMB8MAPT | |
| SCHEMBL3785330 | 0.74 | ALDH1A1 (0.50) | ALDH1A1LMNAPOLBKCNN4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | GRIN1, GABRE, GRIN3A | ALDH1A1 986/4885LMNA 4234/4885POLB 3379/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ALDH1A1 2869/4885LMNA 3549/4885POLB 2257/4885 |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GABRE, GRIN3A | ALDH1A1 986/4885LMNA 4234/4885POLB 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.